Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Efficacy of a New Attenuated IBR Live Vaccine with Double Genetic Deletion gE-/tk- in Front of Experimental BoHV1 Infections. Four Trials Assaying Minimum Dose
Moreno A., Casado C., Roca M. and...
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Read
Objectives: to test the efficacy of a new double deleted (ge-/tk-) live attenuated IBr vaccine (Hiprabovis IBr Marker live, HIPra ), vaccinating with 2 minimum doses (10exp6.3 ccId50/calf) 21 days apart and challenging with a virulent BoHV-1 strain.
Materials and Methods: Vaccination scheme: trial 1 (basic vaccination scheme): 5 seronegative vaccinated calves + 5 seronegative mock-vaccinated control calves trial 2 (duration of immunity): 4 seronegative vaccinated calves + 4 seronegative mock-vaccinated control calves trial 3 (booster dose): 5 seronegative vaccinated calves + 5 seronegative mock-vaccinated control calves trial 4 (influence of maternally derived antibodies): 5 seronegative vaccinated calves + 5 seropositive vaccinated calves + 5 seropositive mock-vaccinated control calves challenge scheme (10exp7 ccId50/ calf, intranasal, BoHV-1 Iowa strain) trial 1: 21 days post-vaccination trial 2: 6 months post-vaccination trial 3: 1 year post-vaccination (6 months after booster) trial 4: when the seropositive control group got seronegative Follow-up after infection for all trials: monitorization for 21 days for - clinical signs (general and respiratory) - rectal temperatures - viral nasal shedding.
Results: trial 1 – great, significant reduction in: respiratory and general clinical signs (72% reduction), increase in body temperature, and viral excretion after challenge (5 days shorter). trial 2 - still a clear, significant reduction in: clinical signs (48%), increase in body temperature, and viral excretion (5 days shorter) after challenge 6 months after vaccination. trial 3 - clear effect of the booster dose with results similar to the previous trial: significant reduction in: clinical signs, increase in body temperature, and viral excretion after challenge 6 months after revaccination (1 year after first vaccination). trial 4 - there were almost no differences between the two vaccinated groups as for the significant reduction in: respiratory and general clinical signs (>50% reduction), increase of body temperature, and viral excretion after challenge (4-6 days shorter), despite the presence or not of maternally derived antibodies at the time of vaccination.
Conclusions: - the efficacy of a new double deleted (ge-/tk-) attenuated live IBr vaccine (Hiprabovis IBr Marker live, HIPra ) was demonstrated up to 6 months after the vaccination scheme was completed and up to 6 months after the booster dose. - the vaccine was also efficacious in the presence of maternally derived antibodies.
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
About
Affiliation of the authors at the time of publication
Laboratorios HIPRA S.A., Spain
Comments (0)
Ask the author
0 comments